SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024
SI-BONE (SIBN) has released preliminary Q4 2024 financial results, showing strong growth across key metrics. The company reported Q4 worldwide revenue between $48.8-$49.0 million, representing approximately 26% growth year-over-year. U.S. revenue reached $46.7-$46.9 million, up about 28%.
For the full year 2024, worldwide revenue was between $167.0-$167.1 million, showing 20% growth, while U.S. revenue reached $158.2-$158.4 million, up 21%. The company expanded its U.S. active physician base to approximately 1,390, representing 23% growth. SI-BONE ended Q4 with approximately $150 million in cash and marketable securities, with net cash use of about $0.8 million in the quarter. Notably, the company achieved adjusted EBITDA profitability in Q4 2024.
SI-BONE (SIBN) ha pubblicato i risultati finanziari preliminari per il quarto trimestre 2024, mostrando una forte crescita nei principali indicatori. L'azienda ha riportato un fatturato globale del quarto trimestre tra 48,8 e 49,0 milioni di dollari, che rappresenta circa il 26% di crescita rispetto all’anno precedente. Il fatturato negli Stati Uniti ha raggiunto 46,7-46,9 milioni di dollari, in aumento di circa il 28%.
Per l'intero anno 2024, il fatturato globale è stato compreso tra 167,0 e 167,1 milioni di dollari, con una crescita del 20%, mentre il fatturato negli Stati Uniti ha raggiunto 158,2-158,4 milioni di dollari, in aumento del 21%. L'azienda ha ampliato la sua base di medici attivi negli Stati Uniti a circa 1.390, rappresentando una crescita del 23%. SI-BONE ha chiuso il quarto trimestre con circa 150 milioni di dollari in contante e titoli negoziabili, con un utilizzo netto di liquidità di circa 0,8 milioni di dollari nel trimestre. È importante notare che l'azienda ha raggiunto la redditività EBITDA corretto nel quarto trimestre 2024.
SI-BONE (SIBN) ha publicado los resultados financieros preliminares del cuarto trimestre de 2024, mostrando un fuerte crecimiento en métricas clave. La compañía reportó ingresos mundiales del cuarto trimestre entre 48,8 y 49,0 millones de dólares, representando aproximadamente un 26% de crecimiento interanual. Los ingresos en EE. UU. alcanzaron 46,7-46,9 millones de dólares, lo que implica un aumento de aproximadamente el 28%.
Para el año completo 2024, los ingresos mundiales se situaron entre 167,0 y 167,1 millones de dólares, mostrando un crecimiento del 20%, mientras que los ingresos en EE. UU. alcanzaron 158,2-158,4 millones de dólares, aumentando un 21%. La compañía amplió su base de médicos activos en EE. UU. a aproximadamente 1.390, lo que representa un crecimiento del 23%. SI-BONE finalizó el cuarto trimestre con aproximadamente 150 millones de dólares en efectivo y valores negociables, con un uso neto de efectivo de aproximadamente 0,8 millones de dólares en el trimestre. Cabe destacar que la compañía alcanzó la rentabilidad del EBITDA ajustado en el cuarto trimestre de 2024.
SI-BONE (SIBN)은 2024년 4분기 예비 재무 결과를 발표하였으며, 주요 지표에서 강력한 성장을 보여주었습니다. 회사는 4분기 전 세계 매출이 4,880만-4,900만 달러 사이임을 보고하며, 전년 대비 약 26% 성장했습니다. 미국 매출은 4,670만-4,690만 달러에 도달하여 약 28% 증가하였습니다.
2024년 전체 연간 매출은 1억6,700만-1억6,710만 달러 사이로 20% 성장하였으며, 미국 매출은 1억5,820만-1억5,840만 달러에 도달하여 21% 증가하였습니다. 회사는 미국의 활성 의사 수를 약 1,390명으로 확대하여 23% 성장을 나타냈습니다. SI-BONE은 4분기를 종료할 때 약 1억5천만 달러의 현금 및 시장성 있는 증권을 보유하고 있으며, 이번 분기에 약 80만 달러의 순 현금 사용이 있었습니다. 주목할 만한 점은 회사가 2024년 4분기에 조정된 EBITDA 수익성을 달성했다는 것입니다.
SI-BONE (SIBN) a publié les résultats financiers préliminaires du quatrième trimestre 2024, montrant une forte croissance dans des indicateurs clés. L'entreprise a rapporté un chiffre d'affaires mondial pour le quatrième trimestre compris entre 48,8 et 49,0 millions de dollars, représentant environ 26% de croissance par rapport à l'année précédente. Le chiffre d'affaires aux États-Unis a atteint 46,7-46,9 millions de dollars, en hausse d'environ 28%.
Pour l'année entière 2024, le chiffre d'affaires mondial était compris entre 167,0 et 167,1 millions de dollars, affichant une croissance de 20%, tandis que le chiffre d'affaires aux États-Unis atteignait 158,2-158,4 millions de dollars, en hausse de 21%. L'entreprise a élargi sa base de médecins actifs aux États-Unis à environ 1 390, représentant une croissance de 23%. SI-BONE a terminé le quatrième trimestre avec environ 150 millions de dollars en liquidités et titres négociables, avec une consommation nette de liquidités d'environ 0,8 million de dollars au cours du trimestre. Notamment, l'entreprise a atteint la rentabilité de l'EBITDA ajusté au quatrième trimestre 2024.
SI-BONE (SIBN) hat die vorläufigen finanziellen Ergebnisse für das vierte Quartal 2024 veröffentlicht, die ein starkes Wachstum in den wichtigsten Kennzahlen zeigen. Das Unternehmen berichtete von einem weltweiten Umsatz im vierten Quartal zwischen 48,8 und 49,0 Millionen US-Dollar, was ungefähr 26% Wachstum im Jahresvergleich entspricht. Der Umsatz in den USA erreichte 46,7-46,9 Millionen US-Dollar, was einem Anstieg von etwa 28% entspricht.
Für das gesamte Jahr 2024 lag der weltweite Umsatz zwischen 167,0 und 167,1 Millionen US-Dollar, was ein Wachstum von 20% zeigt, während der Umsatz in den USA bei 158,2-158,4 Millionen US-Dollar lag, was einem Anstieg von 21% entspricht. Das Unternehmen hat seine aktive Ärzteschaft in den USA auf etwa 1.390 Ärzte erweitert, was einem Wachstum von 23% entspricht. SI-BONE schloss das vierte Quartal mit einem Betrag von etwa 150 Millionen US-Dollar in Bar und marktgängigen Wertpapieren ab, mit einem Netto-Cash-Bedarf von etwa 0,8 Millionen US-Dollar im Quartal. Bemerkenswert ist, dass das Unternehmen im vierten Quartal 2024 die Rentabilität des bereinigten EBITDA erreichte.
- Q4 worldwide revenue growth of 26% to $48.8-$49.0 million
- U.S. revenue growth of 28% to $46.7-$46.9 million
- Achieved adjusted EBITDA profitability in Q4
- 23% growth in active U.S. physicians to 1,390
- Strong cash position of $150 million with minimal quarterly cash burn of $0.8 million
- None.
Insights
SI-BONE's preliminary Q4 results showcase remarkable execution with ~26% revenue growth to
The expansion of the U.S. active physician base by
The accelerating physician adoption rate is particularly noteworthy in the competitive medical device landscape. The growth to 1,390 active U.S. physicians translates to an average revenue per physician of approximately
The achievement of adjusted EBITDA profitability is a critical milestone that typically triggers institutional investor interest in the medical device sector. With a market cap of
Fourth Quarter 2024 worldwide revenue of ~
Achieved adjusted EBITDA profitability in the fourth quarter
SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2024.
Fourth Quarter 2024 Summary (any comparisons are to the prior year period)
- Worldwide revenue between
$48.8 -$49.0 million , representing ~26% growth - U.S. revenue between
$46.7 -$46.9 million , representing ~28% growth - Ended the quarter with ~1,390 active physicians in the U.S., representing ~
23% growth - Cash and marketable securities of ~
$150 million , implying net cash use of ~$0.8 million in the quarter
Fiscal Year 2024 Summary (any comparisons are to the prior year period)
- Worldwide revenue between
$167.0 -$167.1 million , representing ~20% growth - U.S. revenue between
$158.2 -$158.4 million , representing ~21% growth
The fourth quarter and full year 2024 revenue, adjusted EBITDA, and cash and marketable securities are included in this release on a preliminary basis, prior to the completion of SI-BONE's financial closing procedures and audit procedures by its external auditors and therefore may be subject to adjustment. SI-BONE expects to provide fourth quarter and full year 2024 financial results during its fourth quarter 2024 earnings call in late February 2025.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 4,300 physicians in performing a total of over 115,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 160 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
SI-BONE is a registered trademark of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.
Forward Looking Statements
The statements in this press release regarding expectations of future events or results, including SI-BONE’s expectations of continued revenue and procedure growth and financial outlook, contained in this press release are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE's preliminary fourth quarter and full year 2024 revenue and cash and marketable securities, which is subject to continued review by SI-BONE and its auditors and significant adjustments may be made before final results are determined, SI-BONE's ability to introduce and commercialize new products and indications, SI-BONE's ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness on the ability and desire of patients to undergo elective procedures including those using SI-BONE's devices, SI-BONE's ability to manage risks to its supply chain, future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment, and the pace of the re-normalization of the healthcare operating environment including the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE's devices. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in the company's most recent filing on Form 10-K, and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov), especially under the caption "Risk Factors." SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.
Use of Non-GAAP Financial Measures
SI-BONE uses adjusted EBITDA, a non-GAAP financial measures that excludes from net loss the effects of interest income, interest expense, depreciation and amortization, stock-based compensation and income tax expense. SI-BONE believes the presentation of adjusted EBITDA is useful to management because it allows management to more consistently analyze period-to-period financial performance and provides meaningful supplemental information with respect to core operational activities used to evaluate management's performance. SI-BONE also believes the presentation of adjusted EBITDA is useful to investors and other interested persons as it enables these persons to use this additional information to assess the company’s performance in using this additional metric that management uses to assess the company’s performance.
Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease SI-BONE's reported results of operations, management strongly encourages investors to review, when they become available, the company's consolidated financial statements and publicly filed reports in their entirety. The company's definition of adjusted EBITDA may differ from similarly titled measures used by others.
Investor Contact
Saqib Iqbal
Sr. Director, FP&A and Investor Relations
investors@SI-BONE.com
FAQ
What was SI-BONE's (SIBN) Q4 2024 revenue growth rate?
How much cash did SI-BONE (SIBN) have at the end of Q4 2024?
What was SI-BONE's (SIBN) full-year 2024 revenue?
How many active physicians did SI-BONE (SIBN) have in the U.S. by Q4 2024?
Did SI-BONE (SIBN) achieve EBITDA profitability in Q4 2024?
